enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Nivolumab/relatlimab - Wikipedia

   en.wikipedia.org/wiki/Nivolumab/relatlimab

   Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. [10] It contains nivolumab , a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab , a lymphocyte activation gene-3 (LAG-3) blocking antibody. [ 10 ]

3. Bristol Myers' Opdivo+Yervoy Fails To Meet Survival Endpoint ...

   www.aol.com/news/bristol-myers-opdivo-yervoy...

   The trial compared Opdivo + Yervoy to standard-of-care chemotherapy as a first-line treatment for unresectable or metastatic urothelial carcinoma patients whose tumor cells express PD-L1 ≥1%.

4. Bristol Myers' Opdivo Combo Treatment Scores European ...

   www.aol.com/news/bristol-myers-opdivo-combo...

   The European Commission approved Bristol Myers Squibb & Co's (NYSE: BMY) fixed-dose combination of Opdualag (nivolumab and relatlimab) for melanoma patients aged 12 years and above. Melanoma is a ...

5. Bristol Myers' Opdivo+Yervoy Combo Gets FDA Nod for HCC

   www.aol.com/news/bristol-myers-opdivo-yervoy...

   Bristol Myers (BMY) gets FDA approval for the Opdivo and Yervoy combination for the treatment of HCC.

6. Relatlimab - Wikipedia

   en.wikipedia.org/wiki/Relatlimab

   This monoclonal antibody –related article is a stub. You can help Wikipedia by expanding it.

7. Nivolumab - Wikipedia

   en.wikipedia.org/wiki/Nivolumab

   Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. [2] This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal ...

8. Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study

   www.aol.com/news/bristol-myers-bmy-opdivo-yervoy...

   Bristol Myers' (BMY) late-stage study evaluating Opdivo in combination with Yervoy as a first-line treatment for squamous cell carcinoma of the head and neck fails to meet goal.

9. Ipilimumab - Wikipedia

   en.wikipedia.org/wiki/Ipilimumab

   Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this destruction. [8]